This study will examine the quality of life of patients undergoing bone marrow transplantation to treat a blood disease. It will look at how this therapy affects many areas of life, including for example, personal relationships, work, and general emotional state. The information gained may lead to improved ways of dealing with problems that may arise before or during treatment.

Patients receiving bone marrow stem cells donated by a family member may participate in this study. They will be interviewed before treatment begins and will complete questionnaires at the following intervals:

1. day of admission to the hospital

2. day of the transplant

3. 30 days after the transplant

4. 100 days after the transplant

5. 1 year after therapy

6. 2 years after therapy

All questionnaires to be completed after discharge from the hospital will be scheduled during a regular follow-up visit. Each questionnaire takes about 15 to 20 minutes to complete. The information provided is confidential and will not be shared.

Condition
Bone Marrow Transplantation

Further Study Details: 

Expected Total Enrollment:  106

Clinical research in blood stem cell and bone marrow transplantation documents improvements in disease free intervals, disease free survival, and the severity of treatment related toxicities. However, it is important for patients and families to know the quality of life (QOL) they can expect following an allogeneic transplant. In this longitudinal study we will compare the QOL of patients undergoing a non-myeloablative allogeneic peripheral blood stem cell transplant (A-PBSCT) prospectively with that of a myeloablative A-PBSCT. Subjects (n=106) over the age of 18 will be enrolled. Measures of quality of life (Medical Outcomes Study Short Form-MOS SF-36 and Functional Assessment of Cancer Therapy-General and Bone Marrow Transplant - FACT-G and FACT-G/BMT) and symptom distress (Symptom Distress Scale - SDS) will be administered prior to transplant (baseline) and at set interval post transplant. Data will be analyzed using repeated measures analysis of variance and regression analysis.

Genders Eligible for Study:  Both

Criteria

INCLUSION CRITERIA:
Male or female subjects 18 years of age or older.
Able to read English or Spanish.
Hematological disease requiring A-PBSCT.
Signed informed consent for QOL study.

Maryland
      Warren G. Magnuson Clinical Center (CC), 9000 Rockville Pike,  Bethesda,  Maryland,  20892,  United States

Study ID Numbers:  000002; 00-CC-0002
Record last reviewed:  October 12, 2004
Last Updated:  October 13, 2004
Record first received:  March 22, 2000
ClinicalTrials.gov Identifier:  NCT00004994
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08